Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer

被引:22
作者
Mendoza, Dexter P. [1 ]
Lin, Jessica J. [2 ,3 ]
Rooney, Marguerite M. [2 ,3 ]
Chen, Tianqi [4 ]
Sequist, Lecia V. [2 ,3 ]
Shaw, Alice T. [2 ,3 ]
Digumarthy, Subba R. [1 ]
机构
[1] Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,Founders 202, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[4] Harvard Med Sch, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
关键词
ALK; anaplastic lymphoma kinase; lung cancer; metastasis; FACTOR RECEPTOR MUTATION; EML4-ALK FUSION GENE; CLINICORADIOLOGIC CHARACTERISTICS; OPEN-LABEL; CRIZOTINIB; ADENOCARCINOMA; FISH; EGFR; GEFITINIB; ALECTINIB;
D O I
10.2214/AJR.19.21982
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. ALK rearrangements are an established targetable oncogenic driver in non-small cell lung cancer (NSCLC). The goal of this study was to determine the imaging features of the primary tumor and metastatic patterns in advanced ALK-rearranged (ALK+) NSCLC that may be different from those in EGFR-mutant (EGFR+) or EGFR/ALK wild-type (EGFR-/ALK-) NSCLC. MATERIALS AND METHODS. Patients with advanced ALK+, EGFR+, or EGFR-/ ALK- NSCLC were retrospectively identified. Two radiologists concurrently assessed the imaging features of the primary tumor and the distribution of metastases in these patients. RESULTS. We identified a cohort of 333 patients with metastatic NSCLC (119 ALK+ cases, 116 EGFR+ cases, and 98 EGFR-/ALK- cases). Compared with EGFR+ and EGFR-/ ALK- NSCLC, the primary tumor in ALK+ NSCLC was more likely to be located in the lower lobes (53% of ALK+, 34% of EGFR+, and 36% of EGFR-/ALK- tumors; p < 0.05), less likely to be subsolid (1% of ALK+, 11% of EGFR+, and 8% of EGFR-/ALK- tumors; p < 0.02), and less likely to have air bronchograms (7% of ALK+, 28% of EGFR+, and 29% of EGFR-TALK- tumors; p < 0.01). Compared with EGFR+ and EGFR-TALK- tumors, ALK+ tumors had higher frequencies of distant nodal metastasis (20% of ALK+ tumors vs 2% of EGFR+ and 9% of EGFR-/ALK- tumors; p < 0.05) and lymphangitic carcinomatosis (37% of ALK+ tumors vs 12% of EGFR+ and 12% of EGFR-/ALK- tumors; p < 0.01), but ALK+ tumors had a lower frequency of brain metastasis compared with EGFR+ tumors (24% vs 41%; p = 0.01). Although there was no statistically significant difference in the frequencies of bone metastasis among the three groups, sclerotic bone metastases were more common in the ALK+ tumors (22% vs 7% of EGFR+ tumors and 6% of EGFR-/ALK- tumors; p < 0.01). CONCLUSION. Advanced ALK+ NSCLC has primary tumor imaging features and patterns of metastasis that are different from those of EGFR+ or EGFR-ALK- wild type NSCLC at the time of initial presentation.
引用
收藏
页码:766 / 774
页数:9
相关论文
共 50 条
[1]   Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer [J].
Camidge, D. R. ;
Kim, H. R. ;
Ahn, M. -J. ;
Yang, J. C. -H. ;
Han, J. -Y. ;
Lee, J. -S. ;
Hochmair, M. J. ;
Li, J. Y. -C. ;
Chang, G. -C. ;
Lee, K. H. ;
Gridelli, C. ;
Delmonte, A. ;
Garcia Campelo, R. ;
Kim, D. -W. ;
Bearz, A. ;
Griesinger, F. ;
Morabito, A. ;
Felip, E. ;
Califano, R. ;
Ghosh, S. ;
Spira, A. ;
Gettinger, S. N. ;
Tiseo, M. ;
Gupta, N. ;
Haney, J. ;
Kerstein, D. ;
Popat, S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2027-2039
[2]   Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment [J].
Camidge, D. Ross ;
Kono, Scott A. ;
Flacco, Antonella ;
Tan, Aik-Choon ;
Doebele, Robert C. ;
Zhou, Qing ;
Crino, Lucio ;
Franklin, Wilbur A. ;
Varella-Garcia, Marileila .
CLINICAL CANCER RESEARCH, 2010, 16 (22) :5581-5590
[3]   The International Association for the Study of Lung Cancer Staging Project Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer [J].
Chansky, Kari ;
Sculier, Jean-Paul ;
Crowley, John J. ;
Giroux, Dori ;
Van Meerbeeck, Jan ;
Goldstraw, Peter .
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (07) :792-801
[4]   Impact of Reflex EGFR/ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Cheema, Parneet K. ;
Menjak, Ines B. ;
Winterton-Perks, Zoe ;
Raphael, Simon ;
Cheng, Susanna Y. ;
Verma, Sunil ;
Muinuddin, Ahmad ;
Freedman, Ryan ;
Toor, Nevkeet ;
Perera, Joseph ;
Anaka, Matthew ;
Victor, J. Charles .
JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (02) :E130-E138
[5]   CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis [J].
Cheng, Zenghui ;
Shan, Fei ;
Yang, Yuesong ;
Shi, Yuxin ;
Zhang, Zhiyong .
BMC MEDICAL IMAGING, 2017, 17
[6]   Advanced Adenocarcinoma of the Lung: Comparison of CT Characteristics of Patients with Anaplastic Lymphoma Kinase Gene Rearrangement and Those with Epidermal Growth Factor Receptor Mutation [J].
Choi, Chang-Min ;
Kim, Mi Young ;
Hwang, Hye Jeon ;
Lee, Jung Bok ;
Kim, Woo Sung .
RADIOLOGY, 2015, 275 (01) :272-279
[7]   Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer [J].
Dagogo-Jack, Ibiayi ;
Azzolli, Christopher G. ;
Fintelmann, Florian ;
Mino-Kenudson, Mad ;
Farago, Anna F. ;
Gainor, Justin F. ;
Jiang, Ginger ;
Piotrowska, Zofia ;
Heist, Rebecca S. ;
Lennes, Inga T. ;
Temel, Jennifer S. ;
Mooradian, Meghan J. ;
Lin, Jessica J. ;
Digumarthy, Subba R. ;
Batten, Julie M. ;
Robinson, Hayley ;
Nose, Vania ;
Rivera, Miguel ;
Nardi, Valentina ;
Dias-Santagata, Dora ;
Le, Long P. ;
Sequist, Lecia, V ;
Pitman, Martha ;
Shepard, Jo-Anne O. ;
Shaw, Alice T. ;
Iafrate, A. John ;
Lennerz, Jochen K. .
JCO PRECISION ONCOLOGY, 2018, 2 :1-13
[8]   Air bronchogram: A potential indicator of epidermal growth factor receptor mutation in pulmonary subsolid nodules [J].
Dai, Jie ;
Shi, Jingyun ;
Soodeen-Lalloo, Adiilah K. ;
Zhang, Peng ;
Yang, Yang ;
Wu, Chunyan ;
Jiang, Sen ;
Jia, Xiaoli ;
Fei, Ke ;
Jiang, Gening .
LUNG CANCER, 2016, 98 :22-28
[9]   Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status? [J].
Digumarthy, Subba R. ;
Padole, Atul M. ;
Lo Gullo, Roberto ;
Sequist, Lecia V. ;
Kalra, Mannudeep K. .
MEDICINE, 2019, 98 (01) :E13963
[10]   Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis [J].
DiStasio, Marcello ;
Chen, Yigu ;
Rangachari, Deepa ;
Costa, Daniel B. ;
Heher, Yael K. ;
VanderLaan, Paul A. .
CLINICAL LUNG CANCER, 2017, 18 (05) :E349-E356